Thrombopoietin Receptor

Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which promotes proliferation of human Mpl (hMpl) expression and mouse pro B cell line Ba F3. The phosphorylation of JAK2, STAT3, STAT5 and MAPK is induced. Butyzamide has been shown to help increase platelet levels in mouse xenotransplantation trials.

Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation differentiation and platelet production.

Lusutrombopag (Mulpleta) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.

4 -O-Glucosylvitexin (glucosylvitexin) inhibits TPO activity.